• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2017 Fiscal Year Final Research Report

Investigation of cancer stem cell marker CXCR4 in gemcitabine-resistant pancreatic cance

Research Project

  • PDF
Project/Area Number 15K10192
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Digestive surgery
Research InstitutionNagoya City University

Principal Investigator

Takeyama Hiromitsu  名古屋市立大学, 大学院医学研究科, 名誉教授 (00216946)

Co-Investigator(Kenkyū-buntansha) 松尾 洋一  名古屋市立大学, 大学院医学研究科, 准教授 (40381800)
森本 守  名古屋市立大学, 大学院医学研究科, 助教 (60722569)
佐藤 崇文  名古屋市立大学, 大学院医学研究科, 研究員 (10747257)
齊藤 健太  名古屋市立大学, 大学院医学研究科, 助教 (10770240)
Project Period (FY) 2015-04-01 – 2018-03-31
Keywords膵癌 / ゲムシタビン耐性 / CXCR4 / CXCR4 antagonist / 新規膵癌治療薬
Outline of Final Research Achievements

Gemcitabine (Gem) is widely used for chemotherapy for pancreatic cancer, but the effect is not fully satisfactory, and the reason is resistance. We succeeded in establishing a Gem-resistant pancreatic cancer cell line and confirmed that the expression of CXCR4, a cancer stem cell marker, is enhanced along with resistance with DNA microarray. We also found that CXCR4 is involved in the proliferation and infiltration of Gem-resistant pancreatic cancer via cancer stromal interaction, which was confirmed to be suppressed by control of CXCR4 signal such as CXCR4 antagonist. Based on the above findings, we found a new finding that control of CXCR4 is a target for novel therapeutic drugs in Gem-resistant pancreatic cancer.

Free Research Field

消化器外科, 肝胆膵外科

URL: 

Published: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi